Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7525406 | 0.91 | HTT (0.36) | THRBPOLBL3MBTL1ACHEALDH1A1 | |
| SCHEMBL7529760 | 0.86 | POLB (0.34) | POLBL3MBTL1MEN1KMT2AACHE | |
| SCHEMBL7528865 | 0.84 | POLB (0.34) | POLBSMN1; SMN2L3MBTL1ACHEALDH1A1 | |
| SCHEMBL7533134 | 0.84 | ACHE (0.37) | POLBSMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL7528715 | 0.83 | SMN1; SMN2 (0.33) | POLBSMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL7532573 | 0.83 | POLB (0.33) | POLBSMN1; SMN2L3MBTL1KMT2AACHE | |
| SCHEMBL7528229 | 0.83 | ALDH1A1 (0.34) | THRBPOLBSMN1; SMN2L3MBTL1ACHE | |
| SCHEMBL7531082 | 0.83 | SMN1; SMN2 (0.41) | POLBSMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL7531880 | 0.82 | POLB (0.36) | POLBSMN1; SMN2L3MBTL1KMT2AACHE | |
| SCHEMBL7527817 | 0.82 | ACHE (0.35) | POLBSMN1; SMN2L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6476226-B2 | PLATELET GLYCOPROTEIN IIB/IIIA FIBRINOGEN; ANTICOAGULANTS; THROMBOLYTIC AGENTS; THROMBOEMBOLIC DISORDERS; ANTIINFLAMMATORY AGENTS; BONE DISORDERS; ANTITUMOR, -METASTASIS, -ARTHRITIC AGENTS; ASTHMA; PSORIASIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | F13B, F11, FGB | THRB 1106/4885POLB 3542/4885SMN1; SMN2 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.